Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Argiris Symeonidis

Showing results (101-110 of 138) with videos related to

Pageof 14
Sort By:
The Lancet. Haematology|February 5, 2025
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort studyHege Kristin Gravdahl Garelius, Timothy Bagguley, Adele Taylor, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2019
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine RegistryPanagiotis T Diamantopoulos, Vasiliki Pappa, Argiris Symeonidis, et al.
Blood Cancer Journal|March 11, 2018
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study GroupEirini Katodritou, Evangelos Terpos, Sossana Delimpasi, et al.
Annals of Hematology|June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myelomaIvan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
Hematological Oncology|June 5, 2020
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromesVasileios Papadopoulos, Panagiotis T Diamantopoulos, Sotirios G Papageorgiou, et al.
Annals of Hematology|May 21, 2017
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordanceLouise de Swart, Alex Smith, Marius MacKenzie, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Prognostication of the high-risk WM patientEfstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
American Journal of Hematology|April 22, 2011
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 yearsEfstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hatjiharissi, et al.
Haematologica|November 11, 2017
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Chloé Reiniers, Timothy Bagguley, et al.
Pageof 14

Showing results (101-110 of 138) with videos related to

Sort By:
Pageof 14
The Lancet. Haematology|February 5, 2025
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort studyHege Kristin Gravdahl Garelius, Timothy Bagguley, Adele Taylor, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2019
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine RegistryPanagiotis T Diamantopoulos, Vasiliki Pappa, Argiris Symeonidis, et al.
Blood Cancer Journal|March 11, 2018
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study GroupEirini Katodritou, Evangelos Terpos, Sossana Delimpasi, et al.
Annals of Hematology|June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myelomaIvan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
Hematological Oncology|June 5, 2020
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromesVasileios Papadopoulos, Panagiotis T Diamantopoulos, Sotirios G Papageorgiou, et al.
Annals of Hematology|May 21, 2017
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordanceLouise de Swart, Alex Smith, Marius MacKenzie, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Prognostication of the high-risk WM patientEfstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
American Journal of Hematology|April 22, 2011
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 yearsEfstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hatjiharissi, et al.
Haematologica|November 11, 2017
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Chloé Reiniers, Timothy Bagguley, et al.
Pageof 14